New Two-Pronged attack on tough stomach cancers
NCT ID NCT07070466
Summary
This study is testing whether adding a new drug called ivonescimab to standard chemotherapy (FOLFOX) works better for people with advanced stomach or esophagus cancer that is HER2-negative. The goal is to see if this combination can help control the cancer for longer and shrink tumors more effectively than chemo alone. About 40 adults who haven't had treatment for their advanced cancer will receive the drug combination to measure its safety and effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STOMACH CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UCLA
RECRUITINGSanta Monica, California, 90404, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.